Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: Prognosis still poor and prediction difficult

Scandinavian Journal of Rheumatology

Volumn 40, Issue 2, 2011, Pages 127-132

  Hesselstrand, R ^a   Wildt, M ^a   Ekmehag, B ^a   Wuttge, D M ^a   Scheja, A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; UNIPROST;

ADULT; ARTICLE; CARBON MONOXIDE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; MALE; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SCREENING; SURVIVAL RATE; SWEDEN; SYSTEMIC SCLEROSIS; TELANGIECTASIA;

ADULT; AGED; BLOOD PRESSURE; CARBON MONOXIDE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; SWEDEN;

EID: 79952402476     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.508751     Document Type: Article

References (24)

1. Hesselstrand R, Scheja A, Aakesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6. (Pubitemid 28558973)
2. Steen VD, Medsger TA Jr. Changes of causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
3. de Oliveira NC, Dos Santos Sabbag LM, Ueno LM, de Souza R B C, Borges CL, de Sa Pinto AL, et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007;36:458-61. (Pubitemid 350293520)
4. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63.
5. Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
6. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32. (Pubitemid 43974055)
7. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) 2009;48:304-8.
8. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
9. Hofstee HM, Noordegraaf AV, Voskul AE, Dijkmans BA, Postmus PE, Smulders YM, et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2009;68:191-5.
10. Kampolis C, Plastiras S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol 2008;37:278-83. (Pubitemid 351962324)
11. Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009;160:835-43.
12. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for the carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
13. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22. (Pubitemid 36278021)
14. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Öhlin A-K, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 277 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005;44:366-71. (Pubitemid 40361295)
15. Shah AA, Wigley FM, Hummers LK. Teleangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol 2009;37:98-104.
16. Caramaschi P, Volpe A, Tinazzi I, Bambara LM, Carletto A, Biasi D. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 2006;27:203-5. (Pubitemid 46088283)
17. Masi AT, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF, LeRoy EC, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
19. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
20. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the 6-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
21. Wildt M, Hesselstrand R, Åkesson A, Scheja A. Simple counting of nailfold capillary density in systemic sclerosis-9 years' experience. Scand J Rheumatol 2007;36:452-7. (Pubitemid 350293525)
22. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S): 5S-12S. (Pubitemid 38759712)
23. Matucci-Cerinic M, Steen V, Nash P, Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford) 2009;48(Suppl 3): iii8-13.
24. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63. (Pubitemid 41632043)